COMPARE / SEMAGLUTIDE VS TIRZEPATIDE
Semaglutide vs Tirzepatide: Head-to-Head Research
One direct trial settles the weight question; the rest of the comparison is about which evidence base you weigh. Here is the fair read, with the numbers.
The short version
When people search semaglutide vs tirzepatide, they want one answer: which one takes off more weight? The honest answer comes from a single head-to-head trial, SURMOUNT-5, where tirzepatide won on weight — about 20% lost versus about 14% for semaglutide over roughly 17 months [7]. But "more weight" is not the whole story. Tirzepatide hits two gut-hormone receptors instead of one, which likely explains the gap. Semaglutide, meanwhile, has the larger heart-and-kidney outcome evidence so far, and it comes as both a pill and a shot. Below, the numbers sit side by side, and the honest caveats follow. None of this is medical advice.
The one direct head-to-head: SURMOUNT-5
The cleanest comparison is a single randomized trial that gave both drugs to comparable people. In SURMOUNT-5 (n=751), adults with obesity received either semaglutide or tirzepatide for 72 weeks. Tirzepatide produced greater mean weight loss: -20.2% versus -13.7% for semaglutide — a roughly 6.5-percentage-point advantage that was statistically significant (P<0.001) [7]. That is the strongest available evidence on the weight question, because it is head-to-head rather than a cross-trial guess.
Why the gap? Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates a second incretin receptor (GIP) on top of the GLP-1 receptor that semaglutide targets alone. Engaging both pathways is the leading explanation for the larger weight effect.
The numbers, side by side
Read across, not down — these come from different trials except where noted.
| Measure | Semaglutide | Tirzepatide | Source | |---|---|---|---| | Mean weight change, head-to-head, 72 wks | -13.7% | -20.2% | SURMOUNT-5 [7] | | HbA1c and weight, type 2 diabetes | lower | greater | SURPASS-2 [8] | | Weight change vs placebo (own trial) | -14.9% (STEP 1) | n/a here | STEP 1 [1] | | Cardiovascular-outcome trial in obesity | yes (SELECT, -20% MACE) | not established here | SELECT [3] | | Kidney-outcome trial | yes (FLOW, -24%) | not established here | FLOW [6] | | Oral form available | yes | not covered here | StatPearls [11] |
The table is deliberately one-sided where the evidence is one-sided: tirzepatide leads on head-to-head weight, while semaglutide carries the documented cardiovascular and kidney outcome trials summarized on this site [3][6].
Diabetes: SURPASS-2 points the same way
The weight pattern is not isolated. In SURPASS-2, in type 2 diabetes, tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide 1.0 mg at 40 weeks [8]. So across both the obesity and diabetes head-to-head settings, tirzepatide shows the larger metabolic effect on these specific endpoints — a consistent, replicated direction rather than a one-off.
Where semaglutide's evidence is deeper
A fair comparison does not stop at weight. Semaglutide carries the larger cardiovascular-outcomes evidence base to date: SELECT (n=17,604) showed a 20% reduction in major adverse cardiovascular events in people with cardiovascular disease and obesity but no diabetes [3], on top of the earlier SUSTAIN-6 diabetes result [2]. It also has a dedicated kidney-outcomes trial, FLOW, with a 24% reduction in major kidney events [6]. And it is available as both a once-daily pill and a once-weekly injection [11]. A 2025 modelling study compared the two agents' projected 10-year cardiovascular-risk impact, contextualizing — rather than replacing — these head-to-head endpoints [22]. The takeaway is not a winner; it is that "better" depends on which outcome you are weighing.
Tolerability and the practical differences
Weight loss is the headline, but tolerability and form often decide real-world use. Both drugs share the same dominant downside: gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — concentrated during dose escalation and mostly transient [13]. For semaglutide specifically, a dedicated safety review put nausea at roughly one-third of patients [5], and these events are the leading reason people stop. Neither drug is gentle on the stomach in the early weeks, and that titration period shapes who stays on treatment.
The forms differ in a way the weight number hides. Semaglutide is available as both a once-weekly subcutaneous injection and a once-daily oral tablet [11], so a reader who cannot or will not inject has an oral route documented in the literature. Semaglutide's outcome evidence is also the deeper of the two as summarized here — the SELECT cardiovascular trial [3] and the FLOW kidney trial [6] — which matters for people whose goal is organ protection, not the scale alone. The fair summary: tirzepatide currently leads on head-to-head weight, while semaglutide brings the broader documented outcome base and a pill option.
The honest caveats
Two caveats keep this fair. First, head-to-head trials measure averages over a fixed period in selected participants — an individual's result, tolerability and response can differ, and side effects (dominated by gastrointestinal events for both drugs) shape real-world use as much as the headline number [13][5]. Second, the absence of a tirzepatide cardiovascular- or kidney-outcomes result on this site reflects what this digest documents about semaglutide, not a claim that tirzepatide lacks evidence. As always, this is editorial commentary on published trials, not advice on which medicine anyone should use.